Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease

ConclusionVedolizumab treatment in patients with PSC and IBD did not improve liver biochemistry but was associated with improvement in bowel disease and a favourable safety profile.

Source: Alimentary Pharmacology and Therapeutics - January 29, 2018 Category: Drugs & Pharmacology Authors: B. Christensen, D. Micic, P. R. Gibson, A. Yarur, E. Bellaguarda, P. Corsello, J. N. Gaetano, J. Kinnucan, V. L. Rao, S. Reddy, S. Singh, J. Pekow, D. T. Rubin Tags: ORIGINAL ARTICLE Source Type: research